Last reviewed · How we verify
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine
This vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide antigens by conjugating them to diphtheria toxoid, enhancing immunogenicity and immune memory.
This vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide antigens by conjugating them to diphtheria toxoid, enhancing immunogenicity and immune memory. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis.
At a glance
| Generic name | Meningococcal Polysaccharide Diphtheria Conjugate Vaccine |
|---|---|
| Also known as | Menactra® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide capsules from Neisseria meningitidis conjugated to diphtheria toxoid protein carrier. This conjugation converts T-cell-independent polysaccharide antigens into T-cell-dependent antigens, triggering stronger humoral and cellular immune responses. The resulting antibodies provide protection against invasive meningococcal disease by promoting opsonization and complement-mediated bactericidal activity.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis
Common side effects
- Injection site pain/erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever (PHASE1, PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age (PHASE3)
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine (PHASE3)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: